Clobetasol for Vulvar Lichen Sclerosus
Clobetasol propionate 0.05% is the drug of choice for the treatment of VLS according to the BAD 2018 and EADV 2024 guidelines. We explain how it works, how it is used, and what you can expect from it.
What is Clobetasol and Why is it First-Line Treatment
Clobetasol propionate is a very high-potency topical corticosteroid (Class I, the most potent). It works by reducing the local inflammatory response in vulvar tissue: it decreases the activity of T lymphocytes involved in the autoimmune response of VLS, thereby reducing the inflammation that causes tissue damage.
It is the drug with the most clinical support for VLS. The BAD 2018 and EADV 2024 guidelines establish it as a first-line treatment with a Grade A recommendation. Its efficacy in symptomatic control—especially of pruritus—is high in most patients.
What Clobetasol Does and Does Not Do:
It controls inflammation and reduces symptoms. It does not repair already damaged tissue. It does not eliminate autoimmune predisposition. If treatment is discontinued, symptoms usually recur.
How Clobetasol is Used in VLS
The clobetasol regimen for VLS has two distinct phases:
Induction Phase (4-12 weeks)
One daily application to the affected vulvar area, usually at night. The amount needed is minimal—a small amount covers the entire vulva. This phase aims to control active disease.
Maintenance Phase (indefinite)
Once control is achieved, the frequency is progressively reduced: every other day, then twice a week, then once a week. The goal is to find the minimum effective dose that keeps the disease controlled.
Maintenance is indefinite for most patients. Attempting to completely withdraw treatment usually results in relapse.
Application technique matters. Clobetasol should be applied to dry vulvar skin, in a small amount, covering the affected areas—including the perineum and perianal area if involved. It should not be applied inside the vagina.
Side Effects: What You Should Know
The use of potent corticosteroids on thin skin areas raises legitimate concerns about their side effects. In the context of VLS, there are several important points:
> Skin atrophy. Prolonged use of potent topical corticosteroids can lead to additional skin thinning. In VLS, atrophy is already a consequence of the disease itself, so the risk assessment differs from other contexts. With the correct regimen—adequate dose, progressive reduction—the risk of corticosteroid-induced atrophy is manageable.
> Secondary infections. Local immunosuppression can facilitate candida or other infections. If you experience unusual itching or signs of infection, consult your specialist.
> Telangiectasias and stretch marks. These are known side effects of prolonged use of potent topical corticosteroids on thin skin.
> What is not a side effect of clobetasol in VLS: atrophy that existed before starting treatment. It does not worsen pre-existing VLS atrophy if used correctly.
When to Consider Alternatives
Clobetasol does not provide a complete response in all cases. Consider exploring alternatives with your specialist if:
> You have been on the correct regimen for 3-6 months and symptoms persist significantly
> The disease continues to progress with active anatomical changes despite treatment
> You develop intolerance or significant side effects
> Accumulated tissue damage requires an approach that acts on the tissue, not just on inflammation